{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001434265","name":"GENMAB A/S","summary":"Genmab A/S is a Danish biotechnology company specializing in innovative and differentiated antibody therapeutics for cancer and other serious diseases. Its commercialized medicines include EPKINLY (epcoritamab), Tivdak (tisotumab vedotin), and pipeline assets Rina-S (rinatabart sesutecan) and petosemtamab. The company also generates royalties from partnered medicines including DARZALEX (daratumumab) developed with J&J, Kesimpta (ofatumumab) with Novartis, and TEPEZZA (teprotumumab) with Amgen.","people":[],"products":[{"name":"EPKINLY (epcoritamab-bysp)","type":"service","description":"Bispecific antibody co-developed with AbbVie for relapsed/refractory DLBCL and follicular lymphoma."},{"name":"Tivdak (tisotumab vedotin-tftv)","type":"service","description":"Antibody-drug conjugate co-developed with Pfizer for recurrent or metastatic cervical cancer."},{"name":"Rina-S (rinatabart sesutecan)","type":"service","description":"ADC in Phase 3 development for platinum-resistant ovarian, endometrial, and platinum-sensitive ovarian cancers."},{"name":"Petosemtamab","type":"service","description":"Potential first-in-class bispecific antibody with two BTDs for head and neck cancer, acquired via Merus."},{"name":"DARZALEX (daratumumab)","type":"service","description":"Anti-CD38 antibody developed and commercialized by J&J; Genmab receives royalties."},{"name":"DARZALEX FASPRO (daratumumab and hyaluronidase fihj)","type":"service","description":"Subcutaneous formulation of daratumumab commercialized by J&J; approved in smoldering multiple myeloma."},{"name":"Kesimpta (ofatumumab)","type":"service","description":"Anti-CD20 antibody developed and commercialized by Novartis for multiple sclerosis."},{"name":"TEPEZZA (teprotumumab)","type":"service","description":"Antibody developed and commercialized by Amgen; Genmab receives royalties."},{"name":"DuoBody Technology Platform","type":"platform","description":"Proprietary bispecific antibody platform licensed to multiple partners including J&J and Novo Nordisk."}],"partnerships":[{"partner_name":"Johnson & Johnson (Janssen Biotech, Inc.)","partnership_type":"licensing","description":"DuoBody research and license agreement; J&J develops and commercializes daratumumab, amivantamab, teclistamab, talquetamab.","start_date":null},{"partner_name":"AbbVie Inc.","partnership_type":"development","description":"Co-development and commercialization of epcoritamab (EPKINLY/TEPKINLY) for B-cell lymphomas.","start_date":null},{"partner_name":"Pfizer Inc.","partnership_type":"development","description":"Co-development and commercialization of tisotumab vedotin (Tivdak) for cervical cancer.","start_date":null},{"partner_name":"Novartis AG","partnership_type":"licensing","description":"Novartis develops and commercializes ofatumumab (Kesimpta) for multiple sclerosis.","start_date":null},{"partner_name":"Amgen Inc.","partnership_type":"licensing","description":"Amgen develops and commercializes teprotumumab (TEPEZZA); Genmab receives royalties.","start_date":null},{"partner_name":"Novo Nordisk A/S","partnership_type":"licensing","description":"Novo Nordisk submitted BLA for denecimig (Mim8), a DuoBody-based hemophilia A treatment.","start_date":null},{"partner_name":"F. Hoffmann-La Roche AG (Roche)","partnership_type":"development","description":"First Genmab partnership announced in 2009 for ofatumumab program.","start_date":null},{"partner_name":"GlaxoSmithKline (GSK)","partnership_type":"licensing","description":"GSK developed and commercialized Arzerra (ofatumumab) for oncology indications.","start_date":null}],"affiliations":[],"origin":{"leaf":"2abaa8a77f4a253b763da1032ad178395ae74854740297355a6bc279b96a539a","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"7a6747baf60ce66443ad6b01d06332ca714c48be4f52ebd9fab2f79aaa4c54cb","parent":"66249e6ae1404505f951e2bed9de78c31633c1279c3b8d64afde0b55c9e34de6","source":"0001434265-26-000014","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":248,"hourly_limit":500,"remaining":252,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}